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Long-acting glucagon-like peptide 1 receptor agonists are increasingly used to treat type 2 diabetes. An
increase of heart rate (HR) has been observed with their use. To elucidate the role of the cardiac
sympatho-vagal balance as a possible mediator of the reported increase in HR, we performed power
spectral analysis of HR variability (HRV) in patients receiving exenatide extended-release (ER).
Twenty-eight ambulatory patients with type 2 diabetes underwent evaluation at initiation of exenatide-
ER and thereafter at 3 and at 6 months. To obtain spectral analyses of HRV, a computerized acquisition
of 10 minutes of RR electrocardiogram intervals (mean values of ~700 RR intervals) were recorded both
in lying and in standing positions. All patients showed a substantial increase of HR both in lying and in
standing positions. Systolic blood pressure, body weight, and glycated hemoglobin A1c significantly
decreased both at 3 and 6 months compared with basal levels. The low-frequency/high-frequency ratio
varied from 3.05 6 0.4 to 1.64 6 0.2 (P , 0.001) after 3 months and to 1.57 6 0.3 (P , 0.001) after
6months in a lying position and from 4.566 0.8 to 2.246 0.3 (P, 0.001) after 3months and to 2.386 0.4
(P , 0.001) after 6 months in a standing position compared with basal values, respectively. HR var-
iations, induced by exenatide-ER treatment, do not appear to be related to sympathetic autonomic tone.
Of note, we observed a relative increase of vagal influence on the heart.
Copyright © 2018 Endocrine Society
This article has been published under the terms of the Creative Commons Attribution Non-
Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-
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Type 2 diabetes is a complex metabolic disorder characterized by hyperglycemia and asso-
ciated with a high risk of cardiovascular complications. Glucagon-like peptide 1 receptor
(GLP-1R) agonists represent a relatively new class of antihyperglycemic agents that address
most of the pathophysiologicalmechanisms involved in the development of type 2 diabetes [1].
The recent development of longer-acting GLP-1R agonists, including the once-weekly form of
exenatide extended-release (ER), represents an even more practical and acceptable thera-
peutic modality for the treatment of patients affected by type 2 diabetes.
A specific effect of these agents, i.e., a reduction of body weight, is a welcome contrast to the
effects of other treatment options, e.g., sulfonylureas, glitazones, and insulin, all of which tend
to induce an increase in body weight. Moreover, the favorable effects on body weight and
metabolic profile, together with a reduction in blood pressure, could theoretically reduce
Abbreviations: bpm, beats per minute; CAN, cardiac autonomic neuropathy; DB, deep breathing; EC, electrocardiogram; ER, ex-
tended-release; GLP-1, glucagon-like peptide 1; GLP-1R, glucagon-like peptide 1 receptor; Hb, hemoglobin; HF, high frequency; HR,
heart rate; HRV, heart rate variability; LF, low frequency; LS, lying and standing position; NU, normalized unit; PSA, power spectral
analysis; SE, standard error; VR, Valsalva ratio.
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cardiovascular risk [1], but only recent clinical trials have indicated a beneficial role of GLP-
1R agonists on cardiovascular disease [2, 3].
In most GLP-1 trials, a small but substantial increase in heart rate (HR) has been reported
[4]. This effect on HRmay constitute a reason for caution, as it can potentially lead to adverse
outcomes. In fact, some observations seem to suggest that an increase in HR, particularly as a
consequence of b-adrenergic stimulation and/or reduced vagal tonic stimulation, may predict
cardiac morbidity and potential mortality, and it is therefore undesirable [5].
A meta-analysis of data available from randomized controlled trials on GLP-1 analogs
showed that the increase in HRwasmore evident for liraglutide than exenatide administered
twice daily [4]. However, the underlying mechanisms associated with the increase of HR are
still under investigation. The most important mechanism involved in HR regulation is the
sympathetic/parasympathetic balance. However, both autonomic nervous system-dependent
and independent mechanisms have been suggested as possible explanations of the rise in HR
[6, 7].
Power spectral analysis (PSA) of HR variability (HRV) is a noninvasive, practical, and
reproducible tool, able to define the relative balance of the autonomic nervous system at the
cardiac level [8]. The present real-world clinical study was applied specifically to estimate,
during long-acting GLP-1 agonist treatment, the sympatho-vagal balance variations, also
considering that cardiovascular diseases are the major complications of type 2 diabetes [9].
1. Research Design and Methods
A. Patients
This clinical study was devoted to evaluate sympatho-vagal balance during long-acting GLP-
1R agonist treatment. It was not intended to be an interventional study but rather, a pre-
liminary study conducted in an ambulatory setting.
Twenty-eight consecutive outpatients with type 2 diabetes, who initiated treatment with a
long-acting GLP-1 agonist (exenatide-ER administered subcutaneously, once weekly; 2 mg/
dose) for clinical reasons, were included. In our institution (Verona), almost all patients with
type 2 diabetes are periodically evaluated by PSA in an institutional-screening program. The
identified patients were further examined after beginning the treatment, at 3 and 6 months,
Table 1. Baseline Characteristics of Patients and Therapies During the Study (n = 28)
Baseline 3 Month 6 Month
Age, y 62.9 6 9.6
Sex, men/women 13/15
Ethnicity: caucasic (%) 28 (100)
Cardioaspirin (%) 11 (39.3) 11 (39.3) 11 (39.3)
Hypoglycemic agents
Sulfonylureas (%) 16 (57.1) 16 (57.1) 16 (57.1)
Metformin (%) 19 (67.9) 19 (67.9) 19 (67.9)
Pioglitazone (%) 4 (14.3) 4 (14.3) 4 (14.3)
Repaglinide (%) 2 (7.1) 2 (7.1) 2 (7.1)
Alpha glucosidase inhibitor (%) 1 (3.6) 1 (3.6) 1 (3.6)
Antihypertensive therapy
b-Blockers (%) 5 (17.9) 5 (17.9) 5 (17.9)
ACE inhibitors (%) 9 (32.1) 9 (32.1) 9 (32.1)
Sartanics (%) 8 (28.6) 8 (28.6) 8 (28.6)
Calcium antagonists (%) 5 (17.86) 5 (17.86) 5 (17.86)
Diuretics (%) 3 (10.71) 3 (10.71) 3 (10.71)
Hypertension (%) 17 (60.71)
Data are presented as means 6 standard deviation or absolute numbers and percentages.
Abbreviation: ACE, angiotensin-converting enzyme.
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to study the trend of both HR and the sympatho-vagal balance. All patients were already
being treated with hypoglycemic agents (see Table 1), but none of them were being treated
with dipeptidyl-peptidase 4 inhibitors, sodium-glucose cotransporter 2 inhibitors, acarbose,
or insulin. All hypertensive patients were treated with angiotensin-converting enzyme or
angiotensin II receptor blocker inhibitors, and five of themwere taken b-blockers. During the
study, there was no variation either in the type or dose of medications or in the therapy
applying to patients who were already taking antihypertensive drugs. The study was con-
ducted in accordance with the Declaration of Helsinki and its amendments. The study was
approved by the local Ethics Committee. All patients gave their informed consent to par-
ticipate in the study.
B. Clinical and Laboratory Data
Venous blood was drawn from all patients in the morning after an overnight fast. Hemo-
globin A1c (HbA1c) was measured (according to the standard operating procedures of
the International Federation of Clinical Chemistry Reference) using an automated high-
performance liquid chromatography analyzer (Diamat; Bio-Rad Laboratories, Milan, Italy).
The upper limit of normal for our laboratory was 5.8% (40 mmol/mol).
C. PSA
PSA of resting HRV was carried out on all patients in lying and standing positions (LS) to
emphasize parasympathetic and sympathetic predominance, respectively.
A one-channel electrocardiogram (ECG) recorder was used to monitor the ECG trace and
respiratory pattern (impedance based). This was in addition to a sampling of the RR interval,
which was instantaneously calculated in milliseconds in sequence with the relative beat-to-
beat blood pressure value, provided by a finger photopletismograph (Finometer; Finapres
Medical Systems, Enschede, The Netherlands). The RR intervals were recorded over a rel-
atively long, nearly artifact-free period, in this case for precisely 10 minutes in LS conditions.
Mean values of all RR intervals (~600 to 800), recorded in milliseconds in this period, were
calculated (in numbers of ~600 to 800), and HR, as beats per minute (bpm), was obtained.
Signals of RR values (in tachogram form) and the relative beat-to-beat systolic/diastolic
values (in a linear pattern) were instantaneously transmitted and configured for calculation
by means of an analogic/digital transducer, as previously described [10].
For the software, a mathematical autoregressive model was used for the PSA of HRV,
whichwas carried out, as previously described, while the subjectswere quietly lying down and
resting [10]. The power of each component was measured in normalized units (NUs), as these
give a better estimate of the balance between the various components. NUs are obtained by
dividing the frequency band of interest by total power [total HRV minus very low frequency
(LF); see later]. The RR interval series in normal subjects can be broken down, in terms of
cyclic variations around the mean, into three major spectral components that characteris-
tically fall into three principal frequency bands. The LF band, between 0.03 and 0.17 Hz,
normally has a mean central frequency ~0.12 Hz and is thought to represent mainly sym-
pathetic activity and to a much lesser extent, parasympathetic activity, as well as probably
other physiological reflex mechanisms, such as baroreceptorial activity and peripheral va-
somotor tone. It is partially inhibited by b-blockers and enhanced in many situations that
stimulate sympathetic activity (standing, exercise, and mental stress) [11]. The high-
frequency (HF) band, between 0.17 and 0.36 Hz, is synchronized with breathing phases and
closely associated with vagal activity; it is enhanced by vagomimetic drugs and is totally
abolished by atropine [12–14]. Finally, the very LF band (,0.02 Hz) is not under autonomic
control but probably under the influence of the renin–angiotensin system or other possible
hormonalmechanisms [14]. This component was not taken into account in this study, because
our analysis focused on efferent vagal-sympathetic components. PSA of HRV was carried out
in LS to highlight the influence of parasympathetic and sympathetic pathways, respectively
doi: 10.1210/js.2017-00300 | Journal of the Endocrine Society | 55
Downloaded from https://academic.oup.com/jes/article-abstract/2/1/53/4590240
by University of Verona user
on 03 January 2018
[13]. In normal subjects, passive tilt or more simply, standing up is accompanied by an in-
crease in the LF component and a decrease in the HF component of RR variability [11, 13, 14].
The power of each component was measured in NUs, as these give a better estimation of the
balance among the various components. These were obtained by dividing the absolute power
of each spectral component by the total variance of the RR intervals, from which the power of
the continuous component (here, defined as the power density with a frequency between 0 and
0.02 Hz) was removed [11].
D. Cardiovascular Autonomic Assessment
The cardiovascular autonomic assessment was performed following Ewing and Clarke’s
criteria [15] involving the measurement of the HRV in LS, during deep breathing (DB), and
using the Valsalva ratio (VR). Blood pressure, taken both with the patient lying down and
after 2minutes of standing [15], wasmeasuredmanually by the same operator using the same
instrument (Gamma; Heine Optotechnik, Herrsching, Germany) at the same time each
morning after fasting. The mean value of three successive measurements of blood pressure
was calculated. Patients were requested to avoid strenuous physical exercise in the 24 hours
preceding the cardiovascular tests. We advised them not to consume beverages containing
caffeine or alcohol and to avoid smoking before the cardiovascular autonomic tests. No
agreement exists on the number of abnormal cardiovascular tests required to reach a di-
agnosis of confirmed cardiac autonomic neuropathy (CAN) [16]. In light of the evidence
available, experts have proposed that at least two abnormal HR tests (below the fifth per-
centile) are required, and only one abnormal test or two borderline tests (between the fifth and
10th percentiles) indicate a condition of “early or uncertain”CAN. A severe form of autonomic
neuropathy is diagnosed when confirmed CAN is associated with orthostatic hypotension.
DB, LS, and VR are considered as indexes of mainly “cardiovagal” function, with similar high
sensitivity and specificity, whereas the orthostatic hypotension test is considered to be a test
of sympathetic function [17] (more detailed methodological information is described else-
where [18]). The patients in the current study were also evaluated for the presence or the
absence of autonomic dysfunction.
E. Statistical Analysis
The differences intra patients with type 2 diabetes before and after 3 and 6 months of
exenatide-ER treatmentwere analyzed using theWilcoxon test for paired samples; theMann-
WhitneyU test and the linear correlation test were used for all other analyses.P, 0.05 or less
was considered to indicate statistical significance. Data are expressed as the means 6
standard error (SE).
2. Results
Baseline clinical characteristics of the patients are reported in Table 1. The mean age of
participants was 62.7 6 10.0, 53.6% were women, and none had a previous cardiovascular
event. All subjects were caucasic. Aspirin was taken by 39.3% of subjects, all patients were on
renin–angiotensin system inhibitor treatment (16 on angiotensin-converting enzyme and 12
on angiotensin receptor inhibitors), and 10.7% were taking diuretics. Approximately 82% of
subjects were affected by hypertension. As shown in Table 1, medications were not changed
during the study period. All patients completed the 6-month period of the study, and no
adverse effects were reported. In all patients, treatment with exenatide-ER, given once
weekly subcutaneously (Table 2), was associated with a significant increase in HR, both in
lying position, from 75.76 2.1 to 79.16 2.1 bpm at 3months (P, 0.001 vs basal value) and to
77.7 6 2.4 at 6 months (not significant vs basal value), and in standing position, from 83.6 6
2.2 to 86.06 2.4 bpm after 3months (P, 0.05 vs basal value) and to 86.76 2.6 after 6months
(P , 0.05 vs basal value). During the treatment period, systolic blood pressure in lying
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position significantly decreased from 144.6 6 2.6 to 137.2 6 2.8 mmHg after 3 months (P ,
0.001 vs basal value) and to 129.56 2.5 after 6months (P, 0.001 vs basal value), respectively,
whereas diastolic blood pressure decreased from 82.8 6 1.9 to 82.0 6 1.5 mmHg (P = not
significant) after 3 months and to 79.7 6 1.9 mmHg (P , 0.05 vs basal value) after 6 months
(Fig. 1, Table 2). In standing position, systolic blood pressure changed from 142.8 6 3.1 to
132.66 2.5mmHg after 3months (P, 0.001 vs basal value) and to 125.36 2.3 after 6months
(P , 0.001 vs basal value), and diastolic blood pressure decreased from 83.2 6 2.3 to 81.6 6
1.5 mmHg after 3 months (not significant) and to 78.56 2.2 mmHg after 6 months (P, 0.001
vs basal value; Fig. 2, Table 2). Mean HbA1c value before treatment was 8.4 6 0.1% and
decreased to 7.16 0.1% (P, 0.001) after 3months and to 6.86 0.1% after 6months (P, 0.001
vs basal value; Table 2). Mean body weight from 88.5 6 3.7 decreased to 86.0 6 3.6 kg (P ,
0.001) after 3 months and to 85.8 6 3.7 (P , 0.001) after 6 months (Table 2).
Table 2. Different Variables Considered Before Treatment, After 3 and 6 Months of Therapy Both in
Clinostatism and Orthostatism (n = 28)
Weight, kg HbA1c, % LS DB VR
Base 88.5 6 3.7 8.4 6 0.10 1.12 6 0.02 16.4 6 1.4 1.41 6 0.04
3 mo 86.0 6 3.6a 7.1 6 0.15a 1.11 6 0.02 17.3 6 1.4 1.34 6 0.04b












Base 75.7 6 2.1 144.6 6 2.6 82.8 6 1.9 72.1 6 12 131.7 6 19 641.3 6 90 3.05 6 0.4 11,012 6 345
3 mo 79.1 6 2.1a 137.2 6 2.8a 82.0 6 1.5 75.6 6 15 82.5 6 20c 581.0 6 97 1.64 6 0.2a 10,861 6 313
6 mo 77.7 6 2.4 129.5 6 2.5a 79.7 6 1.9b 72.9 6 19 88.1 6 25b 745.7 6 138 1.57 6 0.3a 10,115 6 352b
Standing Position
Base 83.6 6 2.2 142.8 6 3.1 83.2 6 2.3 71.2 6 19 138.3 6 22 684 6 94 4.56 6 0.8 11,962 6 411
3 mo 86.0 6 2.4b 132.6 6 2.5a 81.6 6 1.5 45.9 6 13 68.3 6 10c 574 6 82 2.24 6 0.3a 11,380 6 360b
6 mo 86.7 6 2.6b 125.3 6 2.6a 78.5 6 2.2c 68.7 6 30 115.4 6 42 620 6 129 2.38 6 0.4a 10,917 6 415c
Classic cardiovascular autonomic tests are also reported. Data are expressed as means 6 SE.
Abbreviation: BP, blood pressure.
aP , 0.001 indicate the level of statistical significance; significance vs base.
bP , 0.05 indicate the level of statistical significance; significance vs base.
cP , 0.01 indicate the level of statistical significance; significance vs base.
Figure 1. Systolic and diastolic blood pressure values before treatment and after 3 and
6 months of therapy in a lying position. Data are expressed as means 6 SE. *P , 0.05 and
***P , 0.001 indicate the level of statistical significance (n = 28). ns, not significant.
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PSAofHRVshowed that theLF/HFratio in lying positiondecreased from3.0560.4 to1.646
0.2 (P, 0.001) after 3 months and to 1.576 0.3 (P, 0.001 vs basal value) after 6 months and
in standing position from 4.56 6 0.8 to 2.24 6 0.3 (P , 0.001) after 3 months and 2.38 6 0.4
(P , 0.001 vs basal value) after 6 months (Fig. 3, Table 2). The LF component in the lying
position changed from 131.76 19 to 82.56 20 (P, 0.01) after 3months and to 88.16 25 (NU;
P, 0.05) after 6months, whereas in standing position, from 138.36 22 to 68.36 10 (P, 0.01)
after 3months and to 115.46 42 (not significant) after 6months (Table 2). TheHF component
in the lying position changed from 72.16 12 to 75.66 15 after 3months and to 72.96 19 (NU;
not significant) after 6 months, whereas in standing position, from 71.2 6 10.2 to 45.9 6 13
(not significant) after 3months and to 68.76 30 (NU; not significant ) after 6months. Finally,
the total power density did not change substantially during the therapy period (Table 2). The
classic autonomic tests (LS, DB, and VR) did not vary substantially during the study period,
as shown in Table 2. The pressure rate product, an estimate of the cardiac oxygen con-
sumption, was substantially reduced at 6months in both in lying and in standing position and
at 3months in lying position (Table 2). According to the standardized criteria for the diagnosis
of CAN (see methods section), two patients resulted with confirmed (although not severe)
CAN, three with early CAN, and 23 without CAN.
3. Discussion
Despite the important advances in antihyperglycemic therapies, macrovascular complica-
tions are still the most common cause of death in patients affected by type 2 diabetes [7, 19].
Clinical evidence is consistently growing that collectively demonstrates a beneficial effect of
Figure 2. Systolic and diastolic blood pressure values before treatment and after 3 and 6
months of therapy, both in a standing position. Data are expressed as means 6 SE. **P ,
0.01 and ***P , 0.001 indicate the level of statistical significance (n = 28).
Figure 3. LF/HF ratio before treatment and after 3 and 6 months of therapy in LS. Data are
expressed as means 6 SE. ***P , 0.001 indicates the level of statistical significance (n = 28).
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theGLP-1R agonists on cardiovascular risk [2, 3, 20]. At present, in addition to its antidiabetic
effects, GLP-1R agonists have shown some cardioprotective actions, mainly related to the
reduction in blood pressure levels [1–3]. It has been reported that a reduction of 5.6 mmHg
resulted in an 18% decrease in the risk of death from cardiovascular diseases in patients with
diabetes [21]. Furthermore, it has been suggested that GLP-1 may provide cardiac protection
via an unknown second receptor or by means of metabolic protection [22, 23]. In contrast to
this beneficial effect, there is a consistent evidence of an increase in HR [4, 24]. In our study,
differently from the others, we measured HR in LS. Interestingly, we observed an increase of
HR at 3 months and a trend toward basal at 6 months in the lying position, whereas in the
standing position, in which the sympathetic predominance is emphasized, we observed a
consistent increase in HR with no major changes in blood pressure. Furthermore, our study
confirms an increase of HR during the GLP-1R agonist. However, our study is the evaluation
of the sympatho-vagal balance using the PSA carried out on all patients, in LS, to emphasize
parasympathetic and sympathetic predominance, respectively.
The principal physiological mechanism increasing HR is either an increase in the sym-
pathetic drive or a decrease in the parasympathetic activity. However, until now, the precise
extent to whichGLP-1R agonists induce amodulation of the sympatho-vagal balance remains
unclear, and to the best of our knowledge, only few studies have addressed this topic [25–27].
However, none of these studies involved exenatide-ER or evaluated PSA of resting HRV, both
in lying and in standing positions under controlled conditions in a laboratory, to emphasize
parasympathetic and sympathetic predominance, respectively. In other long acquisition data
studies, obtained by Holter monitoring, more influences could likely occur by environmental
and behavioral factors.
Of note, the main result of our study is a substantial reduced LF/HF ratio after therapy
with the GLP-1R agonist, both in lying and standing positions; an unexpected “shifting” of
sympatho-vagal balance, meaning reduced sympathetic influence and a relatively greater
parasympathetic final influence on the heart. This finding can have clinical implications, as a
shift toward an increased parasympathetic tone can substantiate a protective effect on the
heart. Concordantly with the previous statement, we also observed a substantial reduction of
the pressure rate product at 6 months, indicating decreased cardiac work and less oxygen
consumption by the heart. Interestingly, the pressure-rate product was mainly reduced in a
standing position when a predominant sympathetic tone is expected.
Hence, our findings do not seem to suggest a mediated autonomic effect of the GLP-1R
agonist onHR, and probably othermechanisms are involved. For example, itmight be an effect
of the agonist on the heart, as also recently suggested [25, 26]. In line with this hypothesis,
experimental studies of GLP-1 infusions in murine models have also reported dose-dependent
inotropic and chronotropic effects that were not suppressed by propranolol, thereby suggesting
a different mechanism of action [28]. In studies on animal models using exendin-(9-39) (with
resulting antagonist effects that blocked the increases in both blood pressure and HR), the
hypothesis of a receptor-mediated effect was confirmed when the pharmaceutical was coad-
ministered with GLP-1-(7-36) [29]. In addition, further evidence suggests that the changes in
autonomic function induced by the GLP-1 agonist on the autonomic tone are heterogeneous,
and as the parasympathetic influence on the gut and pancreas is increased, the effect of GLP-1
on blood pressure and HR is conflicting and species specific [7].
Studies on animal models have demonstrated the presence of a GLP-1R on the heart,
particularly on, but not limited to, the myocytes of the sinus atrial node and atria [30, 31].
Interestingly, signaling by means of GLP-1R directly increases the cardiomyocyte glucose
uptake, independently of its insulinotropic actions [32], through the AKT pathway and the
successive glucose transporter type 4 translocation [32], in addition to a cyclic adenosine
monophosphate-induced phosphorylation of cardiac protein. The activation of the latter
pathway also has been reported during the stimulation of cardiac b1 receptors, and oppo-
site effects have also been described, as a result of activating the cholinergic muscarinic
receptors [32].
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Hence, as recently shown in animalmodels, GLP-1R agonistsmay increaseHR bymultiple
mechanisms, including regulation of the autonomic nervous system [33]. More interestingly,
it seems that cardiac GLP-1R circuits controlling HR require neural inputs and do not
function in a heart-autonomous manner [33].
Finally, of note in our data is evidence that shows that patients with early and con-
firmed autonomic neuropathy also showed an improvement, at the end of the study, in the
relative vagal influence on the heart in one traditional autonomic test, i.e., deep breathing,
which it is considered to measure mainly vagal function. Consistently, this potentially
beneficial therapeutic effect has already been reported in diabetic autonomic neuropa-
thy [34].
This study has important limitations to take into account: it does not have a comparison
group, and therefore, we cannot exclude that HR variations may change in a similar manner
with initiation of other drugs, and the number of subjects is limited. Nevertheless, the study
also has some strengths: (1) all subjects were followed and evaluated by a single operator; (2) a
consolidated experimental approach was used to study the autonomic system; (3) PSA of
resting HRV was carried out both in lying and in standing positions, thus emphasizing
parasympathetic and sympathetic predominance, respectively; (4) all ECG acquisitions were
carried out under controlled conditions in a laboratory; and (5) an effort was made not to
change background medications during the study period.
In conclusion, we observed a relative increase in vagal influence on the heart; thus, an effect
of exenatide on the heart frequency might theoretically be suggested. The reduced sympa-
thetic vs parasympathetic balance might be the consequence of a compensatory mechanism,
and in any case, a “more” relative vagal influence on the heart could reduce the risk of
cardiovascular mortality.
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